G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.
तुलना करने के लिए मीट्रिक्स | 456160 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध456160पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −5.5x | −0.5x | |
PEG अनुपात | 0.00 | −0.14 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 12.8x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 13.9% | 47.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.0% | 5.8% | अनलॉक करें |